supported by Techpool Bio-Pharma Co.,Ltd.(grant no.AKR-S005).
Objective:To investigate the anti-tumor effects of an E1B55KD-deleted oncolytic adenovirus,H101,in combination with a humanized anti-PD-1(Programmed cell death protein 1)monoclonal antibody,Camrelizumab.Methods:Anti-t...
目的探讨分化簇47(cluster of differentiation 47,CD47)与接受程序性死亡蛋白-1(programmed cell death protein 1,PD-1)/程序性死亡配体-1(programmed cell death ligand,PD-L1)抑制剂一线治疗的晚期非小细胞肺癌(Non-small cell lung...
Modern medicine faces the formidable challenge of cancer because of its ability to evade immune surveillance and cultivate resistance to conventional therapies. Cancer cells, when overexpressed with CD47, send a “don...
supported by University of Macao(File No.MYRG-GRG2023-00160-ICMS-UMDF,China);the Science and Technology Development Fund,Macao SAR(File No.0015-2022-A1 and 005/2023/SKL,China);as well as the Internal Research Grant of the State Key Laboratory of Quality Research in Chinese Medicine,University of Macao(File No.SKL-QRCM-IRG2023-011,China).
CD47 is an immune checkpoint widely regarded as a‘don't eat me’signal.CD47-based anti-cancer therapy has received considerable attention,with a significant number of clinical trials conducted.While anti-cancer thera...